Joel Beatty
Stock Analyst at Baird
(4.37)
# 431
Out of 4,412 analysts
94
Total ratings
42.24%
Success rate
27.87%
Average return
Main Sectors:
45 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Maintains: Outperform | $83 → $103 | $73.26 | +40.60% | 2 | Apr 17, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $24 → $25 | $12.36 | +102.27% | 2 | Apr 11, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $4 → $3 | $1.76 | +70.45% | 3 | Apr 11, 2024 | |
| CLDI Calidi Biotherapeutics | Maintains: Outperform | $9 → $4.5 | $0.16 | +2,700.25% | 2 | Mar 21, 2024 | |
| LPTX Leap Therapeutics | Maintains: Outperform | $11 → $9 | $3.25 | +176.92% | 2 | Mar 19, 2024 | |
| ALKS Alkermes | Initiates: Outperform | $37 | $24.68 | +49.92% | 1 | Mar 19, 2024 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $108 | $71.71 | +50.61% | 1 | Mar 19, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $40 → $31 | $16.71 | +85.52% | 2 | Mar 12, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $505 → $490 | $372.80 | +31.44% | 3 | Mar 1, 2024 | |
| COGT Cogent Biosciences | Downgrades: Neutral | $14 → $8 | $6.02 | +32.89% | 2 | Feb 26, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $57 → $68 | $44.24 | +53.71% | 3 | Jan 30, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $127 → $104 | $80.91 | +28.54% | 3 | Jan 30, 2024 | |
| ELF e.l.f. Beauty | Initiates: Neutral | $185 | $179.63 | +2.99% | 1 | Jan 30, 2024 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Outperform | $160 | $109.46 | +46.17% | 1 | Jan 3, 2024 | |
| VAXX Vaxxinity | Initiates: Outperform | $7 | $0.12 | +5,903.43% | 1 | Sep 8, 2023 | |
| IMMP Immutep | Reiterates: Outperform | $7 | $2.65 | +164.15% | 3 | Aug 28, 2023 | |
| TCON TRACON Pharmaceuticals | Maintains: Outperform | $140 → $60 | $1.81 | +3,214.92% | 3 | Aug 15, 2023 | |
| INMB INmune Bio | Initiates: Outperform | $16 | $11.29 | +41.72% | 1 | Jun 1, 2023 | |
| CMRX Chimerix | Initiates: Outperform | $7 | $0.90 | +677.86% | 1 | May 23, 2023 | |
| BYSI BeyondSpring | Maintains: Outperform | $4 → $1.25 | $2.13 | -41.31% | 2 | May 2, 2023 | |
| PLRX Pliant Therapeutics | Initiates: Outperform | $44 | $11.81 | +272.57% | 3 | Apr 13, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $60 → $58 | $22.12 | +162.21% | 2 | Feb 7, 2023 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $18 → $24 | $39.94 | -39.91% | 2 | Nov 18, 2022 | |
| EDIT Editas Medicine | Maintains: Outperform | $25 → $18 | $5.32 | +238.35% | 2 | Nov 18, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Underperform | $18 | $26.55 | -32.20% | 3 | Nov 10, 2022 | |
| CRDF Cardiff Oncology | Maintains: Outperform | $9 → $6 | $4.07 | +47.42% | 2 | Aug 29, 2022 | |
| IGMS IGM Biosciences | Maintains: Outperform | $46 → $31 | $9.40 | +229.79% | 2 | Jun 1, 2022 | |
| VIR Vir Biotechnology | Upgrades: Neutral | $36 → $28 | $8.23 | +240.22% | 2 | Mar 3, 2022 | |
| GERN Geron | Initiates: Outperform | n/a | $3.79 | - | 1 | Nov 2, 2021 | |
| BPMC Blueprint Medicines | Maintains: Outperform | n/a | $93.00 | - | 1 | Jun 17, 2021 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Neutral | n/a | $143.31 | - | 2 | Feb 12, 2021 | |
| VNDA Vanda Pharmaceuticals | Downgrades: Neutral | n/a | $4.62 | - | 4 | Jan 14, 2021 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | n/a | $128.77 | - | 2 | Jan 12, 2021 | |
| PTCT PTC Therapeutics | Upgrades: Buy | n/a | $28.57 | - | 5 | Jan 5, 2021 | |
| ELOX Eloxx Pharmaceuticals | Downgrades: Neutral | n/a | $0.81 | - | 1 | Jun 11, 2020 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | n/a | $41.59 | - | 2 | Apr 9, 2020 | |
| DBVT DBV Technologies | Maintains: Buy | n/a | $0.68 | - | 2 | Apr 6, 2020 | |
| AMRN Amarin Corporation | Maintains: Buy | n/a | $0.87 | - | 3 | Apr 1, 2020 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | n/a | $1.17 | - | 1 | Mar 26, 2020 | |
| ESPR Esperion Therapeutics | Upgrades: Buy | n/a | $1.90 | - | 5 | Mar 17, 2020 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | n/a | $21.06 | - | 1 | Oct 11, 2018 | |
| LIFE aTyr Pharma | Upgrades: Neutral | n/a | $1.57 | - | 1 | Aug 17, 2018 | |
| ASNS Actelis Networks | Maintains: Neutral | n/a | $0.78 | - | 2 | Aug 17, 2018 | |
| NVAX Novavax | Maintains: Neutral | n/a | $4.09 | - | 3 | Feb 21, 2018 | |
| KURA Kura Oncology | Maintains: Buy | n/a | $19.65 | - | 1 | Nov 10, 2017 |
Intra-Cellular Therapies
Apr 17, 2024
Maintains: Outperform
Price Target: $83 → $103
Current: $73.26
Upside: +40.60%
Nurix Therapeutics
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $12.36
Upside: +102.27%
Amylyx Pharmaceuticals
Apr 11, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.76
Upside: +70.45%
Calidi Biotherapeutics
Mar 21, 2024
Maintains: Outperform
Price Target: $9 → $4.5
Current: $0.16
Upside: +2,700.25%
Leap Therapeutics
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $3.25
Upside: +176.92%
Alkermes
Mar 19, 2024
Initiates: Outperform
Price Target: $37
Current: $24.68
Upside: +49.92%
Axsome Therapeutics
Mar 19, 2024
Initiates: Outperform
Price Target: $108
Current: $71.71
Upside: +50.61%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Outperform
Price Target: $40 → $31
Current: $16.71
Upside: +85.52%
argenx SE
Mar 1, 2024
Maintains: Outperform
Price Target: $505 → $490
Current: $372.80
Upside: +31.44%
Cogent Biosciences
Feb 26, 2024
Downgrades: Neutral
Price Target: $14 → $8
Current: $6.02
Upside: +32.89%
Ultragenyx Pharmaceutical
Jan 30, 2024
Maintains: Outperform
Price Target: $57 → $68
Current: $44.24
Upside: +53.71%
BioMarin Pharmaceutical
Jan 30, 2024
Maintains: Outperform
Price Target: $127 → $104
Current: $80.91
Upside: +28.54%
e.l.f. Beauty
Jan 30, 2024
Initiates: Neutral
Price Target: $185
Current: $179.63
Upside: +2.99%
Jazz Pharmaceuticals
Jan 3, 2024
Initiates: Outperform
Price Target: $160
Current: $109.46
Upside: +46.17%
Vaxxinity
Sep 8, 2023
Initiates: Outperform
Price Target: $7
Current: $0.12
Upside: +5,903.43%
Immutep
Aug 28, 2023
Reiterates: Outperform
Price Target: $7
Current: $2.65
Upside: +164.15%
TRACON Pharmaceuticals
Aug 15, 2023
Maintains: Outperform
Price Target: $140 → $60
Current: $1.81
Upside: +3,214.92%
INmune Bio
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $11.29
Upside: +41.72%
Chimerix
May 23, 2023
Initiates: Outperform
Price Target: $7
Current: $0.90
Upside: +677.86%
BeyondSpring
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.13
Upside: -41.31%
Pliant Therapeutics
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $11.81
Upside: +272.57%
Arrowhead Pharmaceuticals
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $22.12
Upside: +162.21%
IDEAYA Biosciences
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $39.94
Upside: -39.91%
Editas Medicine
Nov 18, 2022
Maintains: Outperform
Price Target: $25 → $18
Current: $5.32
Upside: +238.35%
Arcturus Therapeutics Holdings
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $26.55
Upside: -32.20%
Cardiff Oncology
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $4.07
Upside: +47.42%
IGM Biosciences
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $9.40
Upside: +229.79%
Vir Biotechnology
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $8.23
Upside: +240.22%
Geron
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.79
Upside: -
Blueprint Medicines
Jun 17, 2021
Maintains: Outperform
Price Target: n/a
Current: $93.00
Upside: -
Alnylam Pharmaceuticals
Feb 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $143.31
Upside: -
Vanda Pharmaceuticals
Jan 14, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.62
Upside: -
Sarepta Therapeutics
Jan 12, 2021
Downgrades: Neutral
Price Target: n/a
Current: $128.77
Upside: -
PTC Therapeutics
Jan 5, 2021
Upgrades: Buy
Price Target: n/a
Current: $28.57
Upside: -
Eloxx Pharmaceuticals
Jun 11, 2020
Downgrades: Neutral
Price Target: n/a
Current: $0.81
Upside: -
Ionis Pharmaceuticals
Apr 9, 2020
Maintains: Buy
Price Target: n/a
Current: $41.59
Upside: -
DBV Technologies
Apr 6, 2020
Maintains: Buy
Price Target: n/a
Current: $0.68
Upside: -
Amarin Corporation
Apr 1, 2020
Maintains: Buy
Price Target: n/a
Current: $0.87
Upside: -
X4 Pharmaceuticals
Mar 26, 2020
Maintains: Buy
Price Target: n/a
Current: $1.17
Upside: -
Esperion Therapeutics
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.90
Upside: -
Syndax Pharmaceuticals
Oct 11, 2018
Maintains: Buy
Price Target: n/a
Current: $21.06
Upside: -
aTyr Pharma
Aug 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $1.57
Upside: -
Actelis Networks
Aug 17, 2018
Maintains: Neutral
Price Target: n/a
Current: $0.78
Upside: -
Novavax
Feb 21, 2018
Maintains: Neutral
Price Target: n/a
Current: $4.09
Upside: -
Kura Oncology
Nov 10, 2017
Maintains: Buy
Price Target: n/a
Current: $19.65
Upside: -